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 ABSTRACT 
 Anaplastic Lymphoma Kinase (ALK) is a transmembrane receptor kinase that 
belongs to the insulin receptor superfamily and has previously been shown to play 
a role in cell proliferation, migration and invasion in neuroblastoma. Activating  ALK
mutations are reported in both hereditary and sporadic neuroblastoma tumours, and 
several ALK inhibitors are currently under clinical evaluation as novel treatments 
for neuroblastoma. Overall, mutations at codons F1174, R1275 and F1245 together 
account for ~85% of reported  ALK mutations in neuroblastoma. NBLW and NBLW-R 
are paired cell lines originally derived from an infant with metastatic  MYCN amplifi ed 
Stage IVS (Evans Criteria) neuroblastoma, at diagnosis and relapse, respectively. Using 
both Sanger and targeted deep sequencing, this study describes the identifi cation of 
distinct  ALK mutations in these paired cell lines, including the rare R1275L mutation, 
which has not previously been reported in a neuroblastoma cell line. Analysis of the 
sensitivity of NBLW and NBLW-R cells to a panel of ALK inhibitors (TAE-684, Crizotinib, 
Alectinib and Lorlatinib) revealed differences between the paired cell lines, and overall 
NBLW-R cells with the F1174L mutation were more resistant to ALK inhibitor induced 
apoptosis compared with NBLW cells. This pair of cell lines represents a valuable pre-
clinical model of clonal evolution of  ALK mutations associated with neuroblastoma 
progression. 
 INTRODUCTION 
 Neuroblastoma is an embryonal tumour, originating 
from progenitor cells of the sympathetic nervous 
system, and is the most common extra-cranial solid 
tumour of childhood. In contrast to other childhood 
cancers, the long-term survival of patients with high-risk 
neuroblastoma remains poor (< 50%) despite intensive 
multimodal therapy, with those that survive often suffering 
from long-term toxicities. Novel targeted therapies which 
may improve survival while reducing toxicity are under 
development. 
 Inhibitors against Anaplastic Lymphoma Kinase 
(ALK), a transmembrane receptor kinase that belongs 
to the insulin receptor superfamily, are under clinical 
evaluation as novel agents to treat neuroblastoma. 
Originally identifi ed in anaplastic large cell lymphoma 
as an oncogenic fusion protein with nucleophosmin 
consequent to a t(2;5)(p23;q35) translocation [ 1 ], 
numerous ALK fusion proteins have since been identifi ed 
in malignancies including lung, breast, colon and renal 
cancer, and activating point mutations in non-small cell 
lung cancer and neuroblastoma (reviewed by [ 2 ]). The 
exact physiological role of ALK remains unclear, however 
studies have shown that it is preferentially expressed in 
the developing nervous system with expression levels 
diminishing postnatally, supporting a role in embryonic 
nervous system development (reviewed by [ 2 ]). The 
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ALK gene located on chromosome 2p23, encompasses 
29 exons, encoding a 1620 amino acid protein with an 
extracellular ligand-binding domain, a transmembrane 
domain, and intracellular juxtamembrane and kinase 
domains [ 3 ]. Activation via ligand binding leads to 
receptor dimerisation, autophosphorylation, adaptor 
protein recruitment and subsequent downstream signal 
transduction through numerous pathways such as RAS/
MAPK, PI3K/AKT and JAK/STAT [ 2 ,  3 ]. 
 In neuroblastoma, ALK has been shown to be 
involved in cell proliferation, migration and invasion 
and ALK mutations have been reported in around 50% 
of hereditary and 8-10% of sporadic cases, occurring 
across all risk groups and more frequently at relapse 
[ 4 – 9 ]. The most common mutation hotspots are located 
within the kinase domain at codons F1174, R1275 and 
F1245, which together account for ~85% of reported 
 ALK mutations and result in a constitutively activated 
protein with  in vitro transforming capabilities [ 6 ]. 
The co-occurrence of the F1174  ALK mutation and 
 MYCN amplifi cation has previously been reported, and 
identifi es patients with a particularly poor outcome 
[ 6 ,  8 ]. In support of this,  in  vivo tissue targeted 
expression of  ALK F1174L leads to the development of 
neuroblastoma in transgenic mice, and cooperates 
with MYCN to accelerate tumour onset with enhanced 
penetrance and lethality [ 10 ,  11 ]. Previous studies 
have also reported that both wt and mutant ALK can 
regulate the transcription of  MYCN [ 12 ], and that  ALK 
is a MYCN target gene [ 9 ]. Low copy number gains 
and amplifi cations of  ALK have also been reported 
in neuroblastoma. Almost without exception,  ALK 
amplifi cation is accompanied by  MYCN amplifi cation [ 6 , 
 8 ,  13 ,  14 ]. In general,  ALK mutations and amplifi cation 
are mutually exclusive, however very rare cases of both 
have been reported [ 15 ,  16 ]. ALK overexpression in 
the absence of mutation or amplifi cation has also been 
reported and may have prognostic signifi cance [ 17 ]. 
 ALK inhibitors have exhibited anti-tumour activity 
in preclinical models of neuroblastoma [ 14 ,  18 ], although 
only modest, responses were observed in a Phase I trial 
of single agent Crizotinib in paediatric patients [ 19 ]. 
Paediatric Phase 2 studies of Crizotinib monotherapy 
in patients with  ALK aberrations (ClinicalTrials.
gov; NCT00939770 and NCT02034981), and Phase I 
evaluation of Crizotinib in combination with existing 
frontline chemotherapies (NCT01606878) are currently 
underway. A recent study of  ALK aberrations in 1,596 
diagnostic neuroblastomas showed that different  ALK 
mutations confer differential oncogenic potential and 
sensitivity to Crizotinib, demonstrating the clinical 
relevance of mutational status for therapeutic stratifi cation 
of ALK therapies for patients [ 6 ]. These observations 
underline the importance of a robust  ALK testing strategy 
for neuroblastoma tumours, and assumptions about the 
clonal stability of  ALK mutations may infl uence whether 
tumours tested at presentation are re-tested at relapse. 
 The current study describes the identifi cation of 
distinct  ALK mutations using both Sanger and targeted 
deep sequencing in the paired NBLW and NBLW-R 
cell lines. The NBLW cell line was established from the 
primary untreated (right) adrenal tumour of a 6 month 
old male patient with  MYCN amplifi ed Stage IVS (Evans 
Criteria) neuroblastoma with metastasis to the liver 
[ 20 ]. The paired cell line, NBLW-R, was derived post-
chemotherapy (4 courses of 70 mg/kg cyclophosphamide 
and 30 mg/m 2 daunomycin) approximately 6 months 
after initial diagnosis from the bone marrow aspirate of 
the patient at disease relapse with evidence of metastatic 
disease to the bone and bone marrow and enlarging liver 
lesions. The patient unfortunately died from the disease 
< 1 year after initial diagnosis [ 20 ]. These paired cell lines 
representing an interesting model of spatial and clonal/
disease evolution are a valuable model for preclinical 
studies. 
 RESULTS AND DISCUSSION 
 Array comparative genomic hybridisation (Array 
CGH) and short tandem repeat (STR) DNA loci 
analyses 
 The molecular karyotypes of NBLW and NBLW-R 
cells were determined by array CGH ( Figure 1A &  1B ) 
and confi rmed that both cell lines were  MYCN amplifi ed as 
previously reported [ 20 ,  21 ], and that neither cell line had 
 ALK copy number abnormalities.  ALK was not included in 
the segmental gains of 2p detected by array CGH, the  ALK
locus being proximal to the 2p breakpoints. A summary of the 
chromosomal gains and losses detected is shown in  Figure 
1A & 1B and summarised in  Table 1A . This is consistent 
with both our own karyotype analysis (Supplementary Figure 
S1) and the previously reported karyotype for the NBLW 
cell line, and confi rms that both cell lines are derived from 
the same patient [ 21 ]. The NBLW-R cell line karyotype is 
previously unpublished (Supplementary Figure S2), and the 
present array CGH results demonstrate that in comparison 
with the NBLW cells ( Figure 1A ) established at diagnosis, the 
relapsed NBLW-R cell line ( Figure 1B ) has several additional 
regions of chromosomal loss indicative of increased genomic 
instability, as previously reported in relapsed neuroblastoma 
[ 22 ]. Interestingly, fl uorescence  in situ hybridisation showed 
that the MYCN homogeneously staining regions (HSRs) is 
present on chromosome 19 in the NBLW cell line, but present 
on chromosome 9 in the NBLW-R cell line (Supplementary 
Figure S3). Independent STR genotyping of NBLW and 
NBLW-R cells confi rmed that both cell lines were established 
from the same patient (Supplementary Figure S4). 
 ALK mutational screening 
 Sanger sequencing of exons 20-29 of  ALK was 
initially used to determine the  ALK status of NBLW and 
NBLW-R cells, and identifi ed a heterozygous R1275L 
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mutation (c.3824G>T; CGA>CTA) in the NBLW cell line 
established at diagnosis ( Figure 1C ) and a heterozygous 
F1174L mutation (c.3522C>A; TTC>TTA) in the 
NBLW-R cell line establish post-treatment at disease 
relapse ( Figure 1D ). Due to the identifi cation of distinct 
mutations, and because Sanger sequencing is unable to 
reliably detect mutations present at < 20%, targeted deep 
sequencing of  ALK mutation hotspots within exons 23, 
 Figure 1: Array CGH results of  A. NBLW and  B. NBLW-R cell lines, depicting chromosomal gains in green and losses in red. 
Chromatograms showing the heterozygous  ALK mutations in  C. NBLW and  D. NBLW-R cells. 
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24 and 25 was performed using the paired-end Illumina 
Hiseq2500® procedure as previously described [ 15 ] to 
determine whether the reciprocal mutations were present 
at a sub-clonal level. Amplicon sequencing (Illumina 
HiSeq2500) achieved an extremely high depth of coverage 
(80,000×). The background base variability (error rate) 
in 10 control samples was 0.017%+/-0.010; thus a base 
frequency > 0.06% was signifi cantly different from 
background noise (Fisher’s exact test). Consistent with 
Sanger sequencing, targeted deep sequencing confi rmed 
the R1275L mutation (c.3824G>T; CGA>CTA) detected 
with a mutated allele fraction of 50.245% ( Table 1B ). In 
the NBLW-R cell line, deep sequencing confi rmed Sanger 
sequencing results and detected the F1174L mutation 
(c.3522C>A; TTC>TTA) with a mutated allele fraction of 
49.599% ( Table 1B ). The deep sequencing data verifi es 
that the reciprocal  ALK mutations were not present at a 
low sub-clonal level. 
 Table 1: A) Summary of the chromosomal gains and losses in NBLW and NBLW-R cell lines. 
 NBLW  NBLW-R 
Gain  
 152Mb at 1p21.2q44  152Mb at 1p21.2q44 
 24 MB at 2p25.3p23.3  24Mb at 2p25.3p23.3 
 38Mb at 17q21.31q25.3  38Mb at 17q21.31q25.3 
 1.4Mb at 19q13.43  1.4Mb at 19q13.43 
Loss  
 96Mb at 1p36.33p21.3 
 132Mb at 2q13q37.3 
 22Mb at 4q21.21q24 
 30Mb at 5q33.1q35.3 
 21Mb at 6q23.3q25.3 
 1.5Mb at 16p13.3  1.5Mb at 16p13.3 
 0.3Mb at 19q13.43  
 B) Base frequencies (mutated allele fractions) at the F1174 and R1275 hotspots in NBLW and NBLW-R cell lines 
 Chr position/
patient N o  Number of reads  T  G  C  A 
 Codon 
change 
 AA 
change 
 Chr2:29432664   %  P-Value  %  P-Value  %  P-Value  %  P-Value   
 Controls (ALL)  2965617  0.01  NS  99.915  NS  0.001  NS  0.074  NS   
 NBLW  273021  50.245  <1E-200  49.731  <1E-200  0.006  NS  0.015  NS  cGa>cTa  R1275L 
 NBLW-R  291705  0.008  NS  99.946  NS  0.001  NS  0.044  NS  -  - 
 Chr position/
patient N o  Number of reads  T  G  C  A 
 Codon 
change 
 AA 
change 
 Chr2:29443695   %  P-Value  %  P-Value  %  P-Value  %  P-Value   
 Controls (ALL)  2725764  0.01  NS  0.002  NS  99.958  NS  0.029  NS   
 NBLW  219604  0.006  NS  0.001  NS  99.961  NS  0.031  NS  -  - 
 NBLW-R  253575  0.006  NS  0.005  NS  50.389  <1E-200  49.599  <1E-200  ttC>ttA  F1174L 
 The base corresponding to the reference genome (Human Genome Browser,  http://genome.ucsc.edu/ ; hg19) is indicated at 
a given coordinate. For a sample to be analysed, the total number of high-quality reads obtained by Hiseq deep sequencing 
is indicated, and the percentage of reads supporting each base (A, C, G, T) is shown. Values reported for controls are 
calculated from the total number of reads for germline controls at the given position. The mean base frequencies observed 
in the control set is also indicated. For each case, the P value refers to the comparison (two-sided Fisher’s exact test) of 
the base frequency observed in the studied sample to that observed in the controls. Abbreviations: NS, not statistically 
signifi cant; AA, amino acid 
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 The two mutations identifi ed in NBLW and 
NBLW-R cells are in line with previous studies which 
have reported F1174 and R1275 as the commonest 
sites of ALK mutation in neuroblastoma [ 6 ]. F1174L 
mutations have been reported in neuroblastoma cell 
lines and tumours, and are well characterised, promoting 
ligand independent autophosphorylation and oncogenic 
transforming capacity  in vitro and  in vivo [ 6 ,  8 ,  18 ]. 
F1174L is reported exclusively in somatic cases [ 3 ], and 
often in  MYCN amplifi ed cases, and is associated with 
both intrinsic and acquired resistance to Crizotinib [ 6 ,  8 , 
 18 ,  19 ,  23 ]. Somatic R1275L mutations have been reported 
in a few primary neuroblastomas but to our knowledge not 
yet in cell lines [ 6 ,  8 ,  13 ,  14 ,  16 ,  24 – 26 ], and although the 
conformational and functional consequences are largely 
unknown, R1275L has been suggested to function through 
the same mechanism as R1275Q [ 27 ]. 
 To our knowledge, this is the fi rst report of 2 distinct 
ALK mutations in cell lines established at diagnosis and 
relapse from the same patient, and of the R1275L mutation 
in a neuroblastoma cell line. The presence of two different 
ALK mutations in the same tumour sample has previously 
been reported [ 13 ,  25 ,  28 ], and a recent study of  ALK 
mutations in paired primary neuroblastoma samples at 
diagnosis and relapse identifi ed a paired sample which 
had different  ALK mutations at diagnosis and relapse but 
at the same locus and resulted in the same amino acid 
substitution [ 7 ]. The presence of distinct mutations in the 
NBLW and NBLW-R cell lines represents an interesting 
pattern of clonal selection, showing elimination of the 
R1275L clone and relapse with a newly mutant F1174L 
clonal sideline. Two recent whole-genome/exome 
sequencing studies of paired neuroblastoma samples 
at diagnosis and relapse have shed light on the clonal 
evolution of neuroblastoma and reported that although 
relapsed samples have a higher incidence of mutations, 
many mutations which were present at diagnosis are 
no longer present at relapse [ 29 ,  30 ]. Our fi ndings 
also support the importance of ALK in neuroblastoma 
pathogenesis, in particular, the presence of the F1174L 
mutation in the relapsed NBLW-R cell line is in line with 
previous reports of the functional cooperation between 
MYCN and F1174L, representing a particularly aggressive 
phenotype [ 6 ,  8 ,  10 ]. It cannot be completely ruled out 
that the alternative mutations may be present below the 
detection limit of the method used in this study. 
 Intra-tumour clonal and spatial heterogeneity may 
also be a possibility, in that the cell line established from 
primary tumour material taken at diagnosis contains 
different clones to the ones which eventually metastasised to 
bone marrow from which the relapsed cell line was derived. 
It is also possible that the mutations occurred during the 
 in vitro establishment and culture of the cell lines by 
providing a selective growth advantage. A previous analysis 
of the CLB-Ba cell line and the patient bone marrow sample 
from which the cell line was derived, identifi ed the  ALK 
mutation in the primary sample at 6.6% and an expansion 
of the mutation to 32.4% in the cell line [ 7 ]. 
 Targeted next generation sequencing (NGS) was 
performed on NBLW and NBLW-R cells for a panel 
of 38 genes of established or potential signifi cance in 
neuroblastoma which was designed in collaboration 
with the SIOPEN Biology Group ( Table 2 ). In addition 
to the above  ALK mutations, a  NF1 (neurofi bromin 1) 
mutation was identifi ed in NBLW cells and a  PTPRD
(protein tyrosine phosphatase, receptor type D) 
mutation in NBLW-R cells. NF1 is a tumour suppressor 
and negative regulator of the RAS/MAPK pathway 
which is downstream of ALK signalling and has 
previously been shown to be mutated or deleted in 
primary neuroblastoma, where low  NF1 expression 
correlated with poor outcome [ 31 ]. The absence 
of the  NF1 mutation in the cell line established at 
relapse is interesting, as a previous study reported an 
increased frequency of genetic aberrations of the RAS/
MAPK pathway in tumours and cell lines at relapse 
[ 29 ]. PTPRD is a tyrosine phosphatase involved in 
neuritogenesis and tumour suppressor which has been 
reported to be inactivated through structural alterations, 
microdeletions and aberrant splicing [ 32 – 34 ]. Low 
PTPRD expression has been associated with high-
risk neuroblastoma, in particular those with  MYCN
amplifi cation [ 34 ] and has been reported to function as 
a tumour suppressor in neuroblastoma by destabilising 
Aurora Kinase A [ 35 ]. The lack of overlap between the 
gene alterations identifi ed in these cell lines established 
from the same patient at diagnosis and relapse further 
highlights an interesting clonal evaluation and is 
consistent with a previous study which identifi ed 
altered mutational burden and signatures in primary and 
relapsed neuroblastoma samples [ 30 ]. 
 ALK mRNA and protein levels in the paired cell 
lines 
 Analysis of basal expression of ALK and MYCN 
in the NBLW and NBLW-R cell lines showed that, 
consistent with their  MYCN amplifi ed status, both 
cell lines expressed high levels of MYCN protein 
( Figure 2A ). Compared with NBLW cells, NBLW-R 
cells expressed higher levels of total and phosphorylated 
(Y1604) ALK ( Figure 2A ). Interestingly, however, 
analysis of downstream signalling through MAPK, AKT 
and STAT3 pathways showed that NBLW cells expressed 
higher levels of pERK, pSTAT3 and pAKT compared 
with NBLW-R cells ( Figure 2A ). This may be due to 
the identifi ed loss of  NF1 in NBLW cells. In addition, 
the higher levels of pERK in NBLW cells compared to 
NBLW-R cells are consistent with our observations of 
the greater sensitivity of NBLW cells to MEK inhibitors, 
Trametinib and MEK162, compared with NBLW-R cells 
( data not shown ). 
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 Table 2: Targeted NGS analysis of NBLW and NBLW-R 
 Cell line  Gene  Chromosome  Alt variant 
read 
 Codon change  Amino acid 
change 
 NBLW  ALK  2  41.8%  cGa/cTa  R1275L 
  NF1  17  98.5%  Gaa/Taa  E91- 1 
 NBLW-R  ALK  2  42.4%  ttC/ttA  F1174L 
  PTPRD  9  61.6%  cCt/cAt  P711H 
 Alt, Alternative;  1 Stop codon 
 Figure 2:  A. ALK protein expression and downstream signalling and  B.  ALK mRNA in NBLW and NBLW-R cells.  C. Photomicrographs 
of the morphological appearance of NBLW and NBLW-R cells. N- and S-type cells are as indicated in the mixed population NBLW cell 
line.  D. ALK and MYCN protein expression in NBLW-N and NBLW-S cells. 
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 Consistent with ALK protein expression, analysis of 
ALK mRNA levels showed that NBLW-R cells expressed 
4.7 fold greater  ALK mRNA than NBLW cells ( Figure 
2B ), and suggests that the differential expression of ALK 
between the cell lines is not solely due to post-translational 
mechanisms such as protein stability. The transcriptional 
control of  ALK has not been fully elucidated; however 
 ALK has previously been reported to be a direct target gene 
of both MYCN and PHOX2B [ 9 ] but, as both cell lines 
show comparable MYCN expression levels, it is unlikely 
to be due to MYCN mediated transcription of  ALK ( Figure 
2A ). Alternatively, the different morphological phenotype 
of N- and S-type mixed population NBLW cells (50% 
N:50% S;  Figure 2C ) versus N-type NBLW-R cells may be 
infl uencing ALK expression, as a previous study observed 
lower levels of ALK expression in S-type versus N-type 
neuroblastoma cells [ 14 ]. Consistent with this, separation 
of NBLW cells into NBLW-N and NBLW-S showed that 
NBLW-N cells expressed higher levels of ALK, as well 
as MYCN, compared with NBLW-S cells ( Figure 2D ), 
despite the presence of the R1275L  ALK mutation in both 
cell types (data not shown). It is also possible that the 
difference is a consequence of the different  ALK mutations 
detected in NBLW and NBLW-R cells, as the R1275L 
mutation present in NBLW cells is not well characterised. 
Although previous studies in neuroblastoma primary 
tumours and cell lines have established that  ALK mutant 
cases expressed higher levels of  ALK mRNA and/or 
protein compared to wt cases, no differences were reported 
between different ALK mutations [ 14 ,  36 ]. 
 Sensitivity of cell lines to ALK inhibitors 
 Studies have previously reported that the presence 
of the F1174L mutation confers relative resistance to 
Crizotinib but not to TAE-684, of which an analogue, 
LDK378 (Ceritinib), is presently in paediatric clinical 
trials (ClinicalTrials.gov; NCT01742286) [ 6 ,  18 ]. 
Second generation ALK inhibitor, Alectinib, and third 
generation, PF-06463922 (Lorlatinib), have also been 
reported to be effective against F1174L mutants [ 37 , 
 38 ]. The sensitivity of NBLW and NBLW-R cells to 
Crizotinib, TAE-684, Alectinib and PF-06463922 were 
determined using XTT cell proliferation assays. Both cell 
lines were found to be sensitive to Crizotinib, TAE-684 
and Alectinib mediated growth inhibition, with TAE-684 
observed to be >10 times more potent than Crizotinib 
and Alectinib ( Table 3 ). No signifi cant differences were 
observed between Crizotinib GI 50 values of NBLW and 
NBLW-R cells ( Table 3 ), however, NBLW-R cells were 
signifi cantly more sensitive to TAE-684 and Alectinib 
mediated growth inhibition compared to NBLW 
cells. In addition, while NBLW-R cells were found to 
be sensitive to the third generation dual ALK/ROS1 
inhibitor, PF-06463922, 50% growth inhibition could 
not be achieved even at the highest tested concentration 
of 10µM in NBLW cells ( Table 3 ). The latter may be 
due to differences in the selectivity of PF-06463922 
towards the different mutations present in NBLW and 
NBLW-R cells, in particular as little is known about 
the R1275L mutation. In addition, aberrations in other 
pathways which infl uence sensitivity to ALK inhibitors 
may be present, such as ROS1. The above data highlight 
interesting differences between different ALK inhibitors 
and their therapeutic potential in the treatment of  ALK
mutant neuroblastoma. 
 Functional analysis using fl ow cytometry and 
caspase 3/7 assays determined the effect of ALK 
inhibitors Crizotinib, TAE-684, Alectinib and PF-
06463922 on NBLW and NBLW-R cells ( Figure 3 ). 
Overall, the results show that Crizotinib, TAE-684 
and PF-06463922 induced a G 1 cell cycle arrest, 
whereas Crizotinib, TAE-684 and Alectinib induced 
dose-dependent apoptosis in NBLW cells ( Figure 3 ). 
In NBLW-R cells, Crizotinib and TAE-684 led to an 
accumulation of cells in G 2 /M, and Alectinib and PF-
06463922 induced a G 1 cell cycle arrest, however all 
tested ALK inhibitors had minimal effects on apoptosis 
( Figure 3 ). The latter is consistent with the more 
aggressive nature of the relapsed cell line, and possibly 
result from aberrations in pathways regulating apoptosis 
acquired during disease relapse. In conclusion, this pair 
of cell lines represents an interesting pre-clinical model 
of clonal evolution and neuroblastoma tumourigenesis, 
and underscore the need for  ALK analysis at both 
diagnosis and relapse to detect additional or different 
 ALK aberrations which may affect response to ALK 
inhibitors. 
 Table 3: 72h GI 50 values for ALK inhibitors in NBLW and NBLW-R cells 
 Cell Line  NBLW  NBLW-R  P -value 
Crizotinib  584.0 ± 41.6 nM  494.2 ± 43.5 nM  0.22 
TAE-684  38.5 ± 3.9 nM  30.2 ± 5.3 nM  0.02 
Alectinib  488.5 ± 49.1 nM  307.3 ± 18.3 nM  0.02 
PF-06463922 (Lorlatinib)  > 10 µM  169.9 ± 20.6 nM  < 0.0001 
 Data represent n ≥ 3 ± SEM. 
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 Figure 3: Sub-G 1 and cell cycle phase distribution of NBLW and NBLW-R cells treated for 24 hours with DMSO, 1× 
or 10× their respective GI 50 concentrations of ALK inhibitors  A. Crizotinib,  B. TAE-684,  C. Alectinib and  D. PF-06463922*. 
Caspase 3/7 activity of NBLW and NBLW-R cells treated for 24 hours with DMSO, 1× or 10× their respective GI 50 concentrations of 
E. Crizotinib,  F. TAE-684,  G. Alectinib and  H. PF-06463922*. *NBLW cells were treated with 10 µM PF-06463922 only. Caspase 3/7 
data are expressed as fold change relative to DMSO control. All data are the average of at least 3 independent experiments and error bars 
represent SEM. 
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 MATERIALS AND METHODS 
 Cell culture and DNA extraction 
MYCN amplifi ed human neuroblastoma cell lines, 
NBLW and NBLW-R were cultured in RPMI 1640 (Sigma, 
Dorset, England) supplemented with 10% v/v Foetal 
Calf Serum (Gibco/Life Technologies Ltd, Paisley, UK). 
Photomicrographs (×20) were captured using a VisiCam® 
digital camera and analyser software (VWR International 
Ltd, Lutterworth, UK). DNA was extracted using the 
DNeasy Blood and Tissue Kit (Qiagen, Manchester, 
UK) according to the manufacturer’s instructions, and 
quantifi ed using the Nanodrop (Thermo Scientifi c, 
Waltham, MA USA). Cell line authentication was 
conducted using the AuthentiFiler™ PCR Amplifi cation 
Kit (Applied Biosystems/Life Technologies Ltd) and 
Promega PowerPlex® 16 HS System according to 
manufacturer’s protocols. 
 Array CGH and targeted NGS 
 Array CGH was performed using Agilent whole 
genome 80×60K oligo array (ISCA version 2.0) and 
Illumina BlueFuse Multi v3.3 analysis software with 
Genome Build GRCh37, providing a resolution of 
below 0.25 Mb. Sanger sequencing was performed using 
standard methods and primer sequences are available 
on request. Illumina HiSeq2500 sequencing was used to 
achieve a very high depth of coverage within  ALK exons 
23, 24 and 25 containing the F1174, F1245 and R1275 
hotspots, respectively. DNA was amplifi ed via a two-step 
PCR approach, the second step consisting of addition of 
sample-specifi c barcodes for targeted resequencing in 
a single experiment. Targeted NGS was performed on a 
panel of 38 genes of established or potential signifi cance 
in neuroblastoma, designed in collaboration with the 
SIOPEN Biology Group:-  NRAS , MDM4 ,  MYCN ,  ALK , 
 IDH1 ,  PIK3CA ,  PDGFRA ,  TERT ,  FGFR4 ,  CDK6 , 
 BRAF , FGFR1 ,  MYC ,  CDKN2A ,  CDKN2B ,  PTCH1, 
TSC1, PTPRD, PTEN ,  HRAS , CCND1 ,  ATM ,  KRAS , 
 CDK4 ,  MDM2 , PTPN11 ,  MAP2K1 ,  TP53 ,  NF1 ,  ERBB2 , 
MAP2K2 ,  ATRX ,  ARID1A ,  ARID1B ,  PDE6G , TENM2 , 
MAP3K13 and  PHOX2B . The Illumina Truseq custom 
amplicon kit was used for NGS library preparation, and 
sequenced using the Illumina NextSeq 550. Analysis was 
carried out using Illumina TruSeq Amplicon BaseSpace 
Amplicon software, Illumina Variant Studio software and 
Alamut® Visual (Interactive Biosoftware, Rouen, France). 
 Cell proliferation assays 
 Cell proliferation was determined using XTT assays 
and GI 50 concentrations calculated as previously described 
[ 39 ]. Crizotinib, TAE-684, Alectinib and PF-06463922 
were obtained from Selleck Chemicals (Munich, 
Germany) and diluted in DMSO (Sigma). All statistical 
tests were performed using GraphPad Prism v6.0 software. 
 Quantitative reverse transcription PCR (qRT-
PCR), protein analysis, fl ow cytometry and 
Caspase 3/7 assays 
 RNA was extracted using RNeasy Mini kit (Qiagen) 
and quantifi ed using the Nanodrop. qRT-PCR was performed 
using inventoried TaqMan Gene Expression Assays (Applied 
Biosystems). RNA expression values were normalised to 
GAPDH and all experiments were performed in triplicate. 
Cell lysates were harvested using PhosphoSafe lysis buffer 
(Merck Millipore Ltd, Feltham, UK) and Western blotting 
carried out as previously described [ 39 ]. Primary antibodies 
used were p ALK (Tyr-1604 and Tyr-1282/83), ALK, p 
ERK, ERK, pAKT, AKT, pSTAT3 (Cell Signaling, Leiden, 
The Netherlands), STAT3 (R&D Systems) MYCN and 
GAPDH (Santa Cruz Biotechnology, Heidelberg, Germany), 
all at 1:1000. Flow cytometry and Caspase 3/7 assays were 
performed as previously described [ 39 ]. 
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